BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure
Go back to BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 246.10 +6.54 (2.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $239.56 | 52 Week High | $109.10 | |||
| Open | $240.37 | 52 Week Low | $31.38 | |||
| Day High | $247.10 | P/E | N/A | |||
| Day Low | $237.97 | EPS | $-1.45 | |||
| Volume | 480,215 | |||||
| (NASDAQ: IONS) | Delayed: 45.06 +0.62 (1.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.44 | 52 Week High | $62.68 | |||
| Open | $44.95 | 52 Week Low | $19.59 | |||
| Day High | $45.25 | P/E | N/A | |||
| Day Low | $44.20 | EPS | $0.00 | |||
| Volume | 2,540,744 | |||||
